Sun Pharmaceutical Industries Ltd
NSE:SUNPHARMA
Sun Pharmaceutical Industries Ltd
Total Other Income
Sun Pharmaceutical Industries Ltd
Total Other Income Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Other Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Sun Pharmaceutical Industries Ltd
NSE:SUNPHARMA
|
Total Other Income
₹18B
|
CAGR 3-Years
25%
|
CAGR 5-Years
17%
|
CAGR 10-Years
19%
|
|
|
Dr Reddy's Laboratories Ltd
NSE:DRREDDY
|
Total Other Income
₹8.4B
|
CAGR 3-Years
23%
|
CAGR 5-Years
6%
|
CAGR 10-Years
N/A
|
|
|
Cipla Ltd
NSE:CIPLA
|
Total Other Income
₹8.2B
|
CAGR 3-Years
44%
|
CAGR 5-Years
19%
|
CAGR 10-Years
16%
|
|
|
Lupin Ltd
NSE:LUPIN
|
Total Other Income
₹1.9B
|
CAGR 3-Years
2%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
1%
|
|
|
T
|
Torrent Pharmaceuticals Ltd
NSE:TORNTPHARM
|
Total Other Income
₹722.9m
|
CAGR 3-Years
-26%
|
CAGR 5-Years
-10%
|
CAGR 10-Years
-9%
|
|
|
M
|
Mankind Pharma Ltd
NSE:MANKIND
|
Total Other Income
₹768.7m
|
CAGR 3-Years
8%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Sun Pharmaceutical Industries Ltd
Glance View
Sun Pharmaceutical Industries Ltd. began its journey in 1983 with a vision to provide quality healthcare to billions worldwide. Originating from India, Sun Pharma has steadily emerged as a global leader in the pharmaceutical industry. The company’s strength stems from its ability to efficiently manufacture, develop, and market a wide range of generic pharmaceuticals and therapeutic formulations. With a significant footprint in over 100 countries, it is driven by a robust pipeline of drugs encompassing key therapeutic areas such as psychiatry, cardiology, neurology, and gastroenterology. A hallmark of Sun Pharma’s strategy has been its strong focus on research and development, specifically in creating affordable medicines that tackle complex medical conditions. The company’s business model revolves around a dual strategy: the development of complex generics and innovative specialty products. This approach allows Sun Pharma to capitalize on both the high-volume, cost-efficient production of off-patent drugs and the value-driven, specialized therapy segments. By leveraging its R&D capabilities, the company explores new drug delivery systems and complex formulations, which not only ensure a steady flow of new product introductions but also enhance its competitive edge in the market. This blend of innovation and scale positions Sun Pharmaceutical Industries Ltd. as a dynamic force in the global pharmaceutical landscape, continually navigating the intricate balance of providing both profitable growth and accessible healthcare solutions.
See Also
What is Sun Pharmaceutical Industries Ltd's Total Other Income?
Total Other Income
18B
INR
Based on the financial report for Dec 31, 2024, Sun Pharmaceutical Industries Ltd's Total Other Income amounts to 18B INR.
What is Sun Pharmaceutical Industries Ltd's Total Other Income growth rate?
Total Other Income CAGR 10Y
19%
Over the last year, the Total Other Income growth was 60%. The average annual Total Other Income growth rates for Sun Pharmaceutical Industries Ltd have been 25% over the past three years , 17% over the past five years , and 19% over the past ten years .
You don't have any saved screeners yet